Abstract:With the continuous development and maturity of anti-tumor immunotherapy technology, immune checkpoint inhibitors as one of the main methods of immunotherapy were increasingly widely used in clinical tumor cases, bringing new hope for many advanced cancer patients with poor response to traditional treatment, but at the same time, reported on adverse reactions of various organs related to this were also increasing, and the immune damage caused by them was harmful to patients, especially immune checkpoint inhibitor-associated pneumonia, immune checkpoint inhibitor-associated myocarditis and immune checkpoint inhibitor-associated encephalitis, which could even seriously endangered the lives of patients. Therefore, it was necessary for clinicians to fully understand and master the mechanism, clinical characteristics, laboratory and imaging examination characteristics, diagnostic criteria and differential diagnosis conditions, and treatment principles of adverse reactions that may be caused by immune checkpoint inhibitors, so as to find a more optimized anti-tumor treatment regimen and actively prepared for the treatment of possible immune-related adverse reactions. In this paper, we reported a case of immune checkpoint inhibitor-associated severe pneumonia, referred to the relevant guidelines, introduced its clinical features, laboratory and imaging findings, difficulties encountered in the diagnosis and treatment process, briefly analyzed the causes, and reviewed the possibility of immune-related pneumonia should be considered when respiratory symptoms occurred in patients receiving immunotherapy; the increased ratio of blood neutrophil count to lymphocyte count, and the increased ratio of eosinophil count to lymphocyte count could be used as indicators to indicate immune-related adverse reactions in patients; bronchoalveolar lavage fluid examination and bronchoscopy and lung biopsy were helpful for the diagnosis; when immune checkpoint inhibitor-associated severe pneumonia occurred, in addition to symptomatic and sup-portive treatment, adequate glucocorticoid-based immunosuppressive therapy should be given in time, and combined with cytokines monoclonal antibodies and other biological agents, immunoglobulin co-therapy, but the current indications for the use of biological agents were not fully clear, and the use of high-dose immunosuppressive drugs might cause the risk of severe infection. Therefore, according to the relevant literature and the findings in the process of clinical diagnosis and treatment, this paper proposed that the serum levels of IL-6, TNF-α, CRP and other inflammatory mediators in patients may be used as a quantitative indication to initiate biological agent therapy and accumulate experience for better solving similar problems in the future.

A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab

Identifying Risk Factors and Biomarkers for Severe CIP in Lung Cancer Patients- a Retrospective Case Series Study.

Clinical Features and Determinants of Disease Severity of Immune Checkpoint Inhibitor-Related Pneumonitis: A Retrospective Study

Clinical Outcomes and Risk Factor of Immune Checkpoint Inhibitors-Related Pneumonitis in Non-Small Cell Lung Cancer Patients with Chronic Obstructive Pulmonary Disease

Immune Checkpoint Inhibitor Increased Mortality in Lung Cancer Patients with Pneumocystis Jirovecii Pneumonia: a Comparative Retrospective Cohort Study

Clinical Characteristics, Management and Prognostic Factors of Immune Checkpoint Inhibitor-Associated Pneumonia in Chinese Cancer Patients

Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management

Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)

Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.

Imaging Mass Cytometry Analysis of immune Checkpoint Inhibitor-Related Pneumonitis: A Case Report

A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis

Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis

[Immune-related severe pneumonia: A case report]

Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.

Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer

Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis

[Pneumocystis Jirovecii Pneumonia in Patients with Lung Cancer: A Review].

Immune checkpoint inhibitor-related pneumonitis following discontinuation of pembrolizumab in a patient with advanced lung adenocarcinoma: a case report and literature review

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.

Predictive value of community-acquired pneumonia severity scores on lung cancer patients with immune checkpoint inhibitor-associated pneumonitis: a retrospective analysis